Shots:
- The P-II MOONSONG trial evaluates the antiviral activity, safety & PK of AT-527 (550/1100 mg, bid) vs PBO in adult patients with COVID-19. The therapy is jointly developed in collaboration with Roche
- The trial did not meet its 1EPs of reduction from baseline in SARS-CoV-2 virus in an overall study population, two-thirds of patients had low-risk with mild symptoms. In high-risk patients, a reduction of viral load of ~0.5 log10 @ 7 Day was observed at both doses, was generally safe & well tolerated
- AT-527 is non-mutagenic & has no effects on fertility & reproduction. The therapy is being evaluated across multiple P-II & III clinical trials & P-III MORNINGSKY data is expected in H2’22
Click here to read the full press release/ article | Ref: Atea Pharma | Image: Atea Pharma
The post Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19 first appeared on PharmaShots.
